SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Aspen Neuroscience, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

11/02/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☑ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Frazier Life Sciences X, L.P.	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially	5	Sole Voting Power 0.00

Owned by Each Reporting Person With:	6	Shared Voting Power 1,674,321.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 1,674,321.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 1,674,321.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 5.8 %
12		Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The percentage listed in row 11 is calculated based on 29,102,905 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering, as set forth in the Issuer's final prospectus filed with the Securities and Exchange Commission (the "SEC") on October 30, 2026.

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons FHMLS X, L.P.
2		Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)
3		Sec Use Only
4		Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 1,674,321.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 1,674,321.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 1,674,321.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

☐

Percent of class represented by amount in row (9)

11

5.8 %

Type of Reporting Person (See Instructions)

12

PN

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 29,102,905 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering, as set forth in the Issuer's final prospectus filed with the SEC on October 30, 2026.

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

FHMLS X, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2

☐ (a)
☑ (b)

3 Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5 Sole Voting Power

0.00

6 Shared Voting Power

1,674,321.00

7 Sole Dispositive Power

0.00

8 Shared Dispositive Power

1,674,321.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

1,674,321.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

☐

Percent of class represented by amount in row (9)

11

5.8 %

Type of Reporting Person (See Instructions)

12

OO

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 29,102,905 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering, as set forth in the Issuer's final prospectus filed with the SEC on October 30, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons James N. Topper	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 1,674,321.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 1,674,321.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,674,321.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 5.8 %	
12	Type of Reporting Person (See Instructions) IN	

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 29,102,905 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering, as set forth in the Issuer's final prospectus filed with the SEC on October 30, 2026.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Patrick J. Heron	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☑ (b)	
3	Sec Use Only	

4	Citizenship or Place of Organization UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 1,674,321.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 1,674,321.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,674,321.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 5.8 %	
12	Type of Reporting Person (See Instructions) IN	

Comment for Type of Reporting Person: The amounts reported in rows 6, 8 and 9 represent shares held directly by Frazier Life Sciences X, L.P. The percentage listed in row 11 is calculated based on 29,102,905 shares of Common Stock that were anticipated to be outstanding following the Issuer's initial public offering, as set forth in the Issuer's final prospectus filed with the SEC on October 30, 2026.

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Aspen Neuroscience, Inc.

(b) Address of issuer's principal executive offices:

10835 Road to the Cure, Suite 100, San Diego, CA, 92121.

Item 2.

(a) Name of person filing:

The entities and persons filing this Schedule 13G (collectively, the "Reporting Persons") are: Frazier Life Sciences X, L.P. ("FLS X") FHMLS X, L.P. FHMLS X, L.L.C. James N. Topper ("Topper") Patrick J. Heron ("Heron")

(b) Address or principal business office or, if none, residence:

The address of the principal place of business for each of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 1001 Page Mill Rd, Building 4, Suite 200B Palo Alto, CA 94304

(c) Citizenship:

The information contained in row 4 of each Reporting Person's cover page to this Schedule 13G is incorporated by reference.

(d) Title of class of securities:

Common Stock, par value $0.0001 per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a) The information contained in row 9 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. FLS X directly holds 1,674,321 shares of Common Stock. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares of Common Stock held by FLS X. Except as specifically stated herein, the filing of this Statement shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13G or a member of a "group" with any other person.

Percent of class:

(b) The information contained in row 11 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

The information contained in row 5 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

(ii) Shared power to vote or to direct the vote:

The information contained in row 6 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

(iii) Sole power to dispose or to direct the disposition of:

The information contained in row 7 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

(iv) Shared power to dispose or to direct the disposition of:

The information contained in row 8 of each Reporting Person's cover page to this Schedule 13G (including the footnotes thereto) is incorporated by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Frazier Life Sciences X, L.P.

Signature: /s/ Jennifer Martin

Name/Title: By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.

Date: 11/09/2026

FHMLS X, L.P.

Signature: /s/ Jennifer Martin

Name/Title: By Jennifer Martin, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.

Date: 11/09/2026

FHMLS X, L.L.C.

Signature: /s/ Jennifer Martin

Name/Title: By Jennifer Martin, CFO of FHMLS X, L.L.C.

Date: 11/09/2026

James N. Topper

Signature: /s/ Jennifer Martin

Name/Title: By Jennifer Martin, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney

Date: 11/09/2026

Patrick J. Heron

Signature: /s/ Jennifer Martin

Name/Title: By Jennifer Martin, Attorney-in-Fact for Patrick Heron, pursuant to a Power of Attorney

Date: 11/09/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement

EXHIBIT 99.1

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Shares of Common Stock of Aspen Neuroscience, Inc.

Date: November 9, 2026

FRAZIER LIFE SCIENCES X, L.P.
By: FHMLS X, L.P., its General Partner
By: FHMLS X, L.L.C., its General Partner

By: /s/ Jennifer Martin
Jennifer Martin, Chief Financial Officer

Date: November 9, 2026

FHMLS X, L.P.
By: FHMLS X, L.L.C., its General Partner

By: /s/ Jennifer Martin
Jennifer Martin, Chief Financial Officer

Date: November 9, 2026

FHMLS X, L.L.C.

By: /s/ Jennifer Martin
Jennifer Martin, Chief Financial Officer

Date: November 9, 2026

By: *
James N. Topper

Date: November 9, 2026

By: *
Patrick J. Heron

Date: November 9, 2026

By: /s/ Jennifer Martin
Jennifer Martin, as Attorney-in-Fact

* This Joint Filing Agreement was executed by Jennifer Martin on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on January 27, 2026.